Efstathiou JA - Search Results

1

Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer.

Mouw KW, Miyamoto DT, Efstathiou JA. Mouw KW, et al. Among authors: efstathiou ja. Eur Urol. 2019 Jul;76(1):71-72. doi: 10.1016/j.eururo.2019.03.009. Epub 2019 Mar 23. Eur Urol. 2019. PMID: 30910345 No abstract available.

2

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Efstathiou JA, et al. Urology. 2006 Aug;68(2):342-7. doi: 10.1016/j.urology.2006.02.030. Urology. 2006. PMID: 16904449

3

Bladder-sparing approaches to invasive disease.

Efstathiou JA, Zietman AL, Kaufman DS, Heney NM, Coen JJ, Shipley WU. Efstathiou JA, et al. World J Urol. 2006 Nov;24(5):517-29. doi: 10.1007/s00345-006-0114-y. World J Urol. 2006. PMID: 17082940 Review.

4

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Efstathiou JA, et al. Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15. Eur Urol. 2008. PMID: 18243498 Clinical Trial.

5

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL. Efstathiou JA, et al. Eur Urol. 2012 Apr;61(4):705-11. doi: 10.1016/j.eururo.2011.11.010. Epub 2011 Nov 12. Eur Urol. 2012. PMID: 22101114

6

Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.

Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, McGovern F, Shipley WU. Eswara JR, et al. Among authors: efstathiou ja. J Urol. 2012 Feb;187(2):463-8. doi: 10.1016/j.juro.2011.09.159. Epub 2011 Dec 15. J Urol. 2012. PMID: 22177159

7

Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Gray PJ, et al. Among authors: efstathiou ja. Eur Urol. 2013 May;63(5):823-9. doi: 10.1016/j.eururo.2012.11.015. Epub 2012 Nov 19. Eur Urol. 2013. PMID: 23200811

8

Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

Efstathiou JA, Shipley WU. Efstathiou JA, et al. Eur Urol. 2013 Jan;63(1):181-2. doi: 10.1016/j.eururo.2012.10.032. Eur Urol. 2013. PMID: 23218494 No abstract available.

9

Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.

Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Mitin T, et al. Among authors: efstathiou ja. Curr Urol Rep. 2013 Apr;14(2):109-15. doi: 10.1007/s11934-012-0301-x. Curr Urol Rep. 2013. PMID: 23341373 Review.

10

Clinical controversies: proton therapy for prostate cancer.

Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Mouw KW, et al. Among authors: efstathiou ja. Semin Radiat Oncol. 2013 Apr;23(2):109-14. doi: 10.1016/j.semradonc.2012.11.009. Semin Radiat Oncol. 2013. PMID: 23473687 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters